Accordingly, the aims of the current study were to determine clinicopathological and IHC characteristics predictive of pCR to NAT in a retrospective HER2+ breast cancer cohort and to validate the role of pCR as a surrogate to survival. The gene discussed is ERBB2; the disease is breast cancer.